Management of OAB in Female Patients .
Not Applicable
Completed
- Conditions
- Overactive Bladder
- Interventions
- Registration Number
- NCT06184334
- Lead Sponsor
- Elsayed Abdelhalim Elsayed
- Brief Summary
The objective of this study is to compare the effectiveness of mirabegron, solifenacin, tadalafil (5mg), and their combination in relieving symptoms of overactive bladder (OAB) in a double-blinded prospective randomized placebo-controlled trial.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 300
Inclusion Criteria
- Women from 18 to 65 years of age with LUTs due to OAB
Read More
Exclusion Criteria
-
Severe cardiovascular disorders. \
- Severe neurogenic dysfunction.
- Drug administration which interfere with bladder function .
- Abnormal bleeding profile.
- A verified urinary tract infection as determined by urinalysis and/or urine culture during screening
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group A : patients will receive mirabegron Mirabegron patients will receive mirabegron Group C: patients will receive solfenacin Solfenacin patients will receive solfenacin Group B: patients will receive tadalafil 5mg Tadalafil 5mg patients will receive tadalafil 5mg
- Primary Outcome Measures
Name Time Method overactive bladder symptoms score (OABSS) three months OABSS is a symptom assessment questionnaire designed to quantify OAB symptoms into a single score The questionnaire consists of 4 questions on OAB symptoms with maximum scores ranging from 2 to 5: daytime frequency (2 points), night-time frequency (3 points), urgency (5 points), and UUI (5 points). The total score ranges from 0 to 15 points, with higher scores indicating higher symptom severity.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Kafrelsheikh University hospital
🇪🇬Kafr Ash Shaykh, Egypt